Pharmaceuticals
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody independently developed by the company, in combination with drugs...
2023-09-25 07:41
3574
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with advanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). - ATG-031,discovered and developed in-house by Antengene,is the world's firs...
2023-09-21 18:05
3045
Yuyu Healthcare Conducts Global Promotion at Vitafoods Asia 2023
SEOUL, South Korea, Sept. 21, 2023 /PRNewswire/ -- Yuyu Healthcare will
participate in the Vitafoods Asia 2023 event inBangkok, Thailand with the goal
of entering the global market.
2023-09-21 14:06
6967
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
HANGZHOU, China, Sept. 21, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, today announced the successful completion of Series C2 financing. This round of financing was jointly participated by the Shaox...
2023-09-21 08:00
4928
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today it has entered into a collaboration and license...
2023-09-21 07:05
3894
European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
* Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients inEurope die annually from the disease² * ORSERDU is the first treatment specifically for patients with ER+, HE...
2023-09-20 23:27
3505
AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmologic, neurological and psychiat...
2023-09-20 09:00
4362
Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis
SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, announced today that the Center for Drug E...
2023-09-20 08:26
3171
Cerecin strengthens position in neurometabolism with addition to pipeline
* Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and usein positron emission tomography (PET) studies of ketone body metabolism * Company expands ketogenic platform following pilot data of CER-0001 in migraine and infantile spasms. ...
2023-09-19 19:39
3299
Canton Biologics Completes Over 300 Million Yuan Series C Financing, Led by SDIC Venture Capital
GUANGZHOU, China, Sept. 18, 2023 /PRNewswire/ -- On September 13th, Canton Biologics Co., Ltd. announced that it had recently completed a Series C financing round exceeding300 million yuan. This round of financing was led by SDIC Venture Capital, with participation from Guangdong Technology Finan...
2023-09-18 18:43
4052
Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023
SINGAPORE, Sept. 18, 2023 /PRNewswire/ -- On September 14, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") was the recipient of the prestigious "Most Promising Cell Therapy Pipeline in APAC" award at the 7th Annual Cell & Gene Therapy World Asia 2023, amidst a pool of internation...
2023-09-18 17:53
2915
New drug class prevents key ageing mechanism in organ transplants
ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ -- A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs. The pioneering research, presented today at the European Societ...
2023-09-18 06:01
2887
YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection
GAITHERSBURG, Md., Sept. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2023-09-15 20:30
3265
Neoss® Group has launched a new wireless intraoral scanner, NeoScan™ 2000
ZURICH, Sept. 15, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in
dental implant solutions, is proud to announce the fast and easy-to-use
wireless intraoral scanner, NeoScan™ 2000. This follows the success of last
year's launch of the NeoScan™ 1000.
2023-09-15 16:00
2738
Green Leadership Award Presented to Chugai Pharma Taiwan at the Asia Responsible Enterprise Awards 2023
SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2023 is pleased to honor 30 outstanding business leaders and enterprises for championing sustainable and responsible business practices. Presented by leading regional NGO Enterprise Asia, the AREA is the mo...
2023-09-15 11:37
2596
MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study
GENEVA, Sept. 15, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimu...
2023-09-15 08:00
3305
Foundry Mixer Healthcare, Indonesian Minister of Health Budi G. Sadikin: "Together We Leapfrog Indonesia's Healthcare Transformation"
Indonesian Minister of Health, Budi Gunadi Sadikin, emphasized that investing in the Health Technology and Biotechnology sector serves not only business prospects but also strengthens Indonesia's health resilience and adds value to healthcare. JAKARTA, Indonesia, Sept. 14, 2023 /PRNewswire/ -- F...
2023-09-14 17:47
2683
Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan
SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials inJapan. The former specialises in clinical trial site recruitment and retention and project managemen...
2023-09-14 10:00
4528
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...
2023-09-13 20:29
4282
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets
SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...
2023-09-13 10:30
4361
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 293 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 270 media titles]
2026-10-22 11:55Carro Establishes Inaugural SGD450 Million Asset-Backed Securitisation Warehouse Facility
[Picked up by 267 media titles]
2026-10-22 11:00Most Read
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
17276
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
2026-10-19 13:18
12956
FinDev Canada provides a USD 60 million loan to Muangthai Capital to advance gender equality and private sector investment in Thailand
2026-10-17 00:54
12898
BUUU Group Limited Announces 10-for-1 Forward Share Split
2026-10-17 04:30
12388